Market Access News | pharmaphorum

News

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or

News

CHMP turns down Neuraxpharm, Apellis drugs

The EMA’s human medicines committee refused marketing approvals for two drugs from Neuraxpharm and Apellis at its January meeting, but both companies have said they will a

News

Britain will be first to get new Mounjaro device, says Lilly

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment

News

Remote Parkinson’s monitoring tech backed by NICE

In its second guidance on digital health technologies within a week, NICE has endorsed five remote monitoring devices for patients with Parkinson’s disease that can be use

News

AZ may get government aid for UK vaccines facility; report

The UK government is reportedly considering a financial aid package to encourage AstraZeneca to invest in an expansion of its vaccines manufacturing facility in Speke, nea

News

DiMe project will develop recipe for digital health success

A consortium led by the Digital Medicine Society (DiMe) has been formed to tackle a thorny problem for digital health product (DHP) developers – how to bring them to marke

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

CHMP turns down Neuraxpharm, Apellis drugs

Britain will be first to get new Mounjaro device, says Lilly

Remote Parkinson’s monitoring tech backed by NICE

AZ may get government aid for UK vaccines facility; report

DiMe project will develop recipe for digital health success

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks